Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Chi-Med Raises $100 Million in Private Placement for Cancer Drugs

publication date: Jun 26, 2020

Hutchison China MediTech (Chi-Med) will sell $100 million of its US-listed ADSs to General Atlantic in a private placement. General Atlantic, a growth equity investor, will pay $25 each for the ADSs. General Atlantic has an 18-month option to invest another $100 million in Chi-Med at $30 per ADS. Chi-Med's previous closing price was $26.11. The company, which has a market cap of $3.2 billion and $220 million of cash, will use the proceeds to develop its novel seven-candidate portfolio. More details....

Stock Symbol: (NSDQ/AIM: HCM)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.